🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Oil Down, Investors Digest Surprise U.S. Crude Oil Supply Draw

Published 17/03/2021, 01:38 pm
© Reuters.
LCO
-
CL
-
AZN
-

By Gina Lee

Investing.com – Oil was down Wednesday morning in Asia but steadied after the U.S. reported a surprise draw in crude oil supplies.

Brent oil futures edged down 0.20% to $68.25 by 10:37 PM ET (2:37 AM GMT) and WTI futures inched down 0.09% to $64.74.

Tuesday’s U.S. crude oil supply data from the American Petroleum Institute (API) showed a surprise draw of 1 million barrels for the week ending Mar. 12. Forecasts prepared by Investing.com had predicted a build of 2.715 million barrels, whiles a 12.792-million-barrel build was reported during the previous week.

API data also showed U.S. gasoline inventories dropped by 926,000 barrels during the previous week, while distillate stockpiles rose by 904,000 barrels.

Investors await supply data from the U.S. Energy Information Administration (EIA), which is due later in the day. Should EIA data also point to a draw in stockpiles, it would be the first draw since mid-February after weeks of gains following an unexpected cold snap in Texas and the surrounding areas.

Also on investors’ radars are the monthly International Energy Agency report and the U.S. Federal Reserve’s policy decision, due later in the day, which could help gauge fuel demand recovery and the possibility of higher liquidity.

Despite the recent trend downwards, the black liquid is still up almost 34% in 2021, boosted by Organization of the Petroleum Exporting Countries and allies (OPEC+) production cuts in place until April, and growing fuel demand recovery optimism as COVID-19 vaccines continue to be rolled out globally.

Meanwhile, fears about potential side effects in the AstraZeneca (NASDAQ:AZN) PLC/University of Oxford COVID-19 vaccine continue to hamper fuel demand recovery in Europe, with Sweden and Latvia the latest countries to suspend usage of the vaccine. The European Medicines Agency said it was investigating reports of the side effects, with the findings to be released on Thursday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.